Related Experiment Video
Updated: Jul 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma
Naciye Demirel Yildirim1, Mesut Ayer, Reyhan Diz Küçükkaya
1Division of Hematology, Department of Internal Medicine, University, Istanbul, Turkey. ty@ttnet.net.tr
Abstract:
Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects. Thalidomide's most common side effects are constipation, neuropathy, fatigue, sedation, rash, tremor and peripheral edema. We achieved complete response with a 400 mg/day dose thalidomide therapy in a 58-year-old male patient diagnosed with relapsing refractory multiple myeloma. While continuing thalidomide for sustainable response, the therapy was terminated at the ninth month due to development of leukocytoclastic vasculitis. We describe the case and discuss the place of thalidomide in the treatment of multiple myeloma and the rare occurrence of leukocytoclastic vasculitis during thalidomide therapy in multiple myeloma, since only one such case has been reported in the literature thus far.
Related Concept Videos
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Graves Disease II: Pathophysiology
Cytotoxic Edema: Pathophysiology
Drugs that Destabilize Microtubules
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Cytomegalovirus Disease